CNS Drugs

, Volume 25, Issue 3, pp 187–201 | Cite as

Role of Cannabinoids in Multiple Sclerosis

  • John P. ZajicekEmail author
  • Vicentiu I. Apostu
Review Article


Although extracts from the cannabis plant have been used medicinally for thousands of years, it is only within the last 2 decades that our understanding of cannabinoid physiology and the provision of evidence for therapeutic benefit of cannabinoids has begun to accumulate. This review provides a background to advances in our understanding of cannabinoid receptors and the endocannabinoid system, and then considers how cannabinoids may help in the management of multiple sclerosis (MS).

The relative paucity of treatments for MS-related symptoms has led to experimentation by patients with MS in a number of areas including the use of cannabis extracts. An increasing amount of evidence is now emerging to confirm anecdotal reports of symptomatic improvement, particularly for muscle stiffness and spasms, neuropathic pain and sleep and bladder disturbance, in patients with MS treated with cannabinoids. Trials evaluating a role in treating other symptoms such as tremor and nystagmus have not demonstrated any beneficial effects of cannabinoids. Safety profiles of cannabinoids seem acceptable, although a slow prolonged period of titration improves tolerability. No serious safety concerns have emerged.

Methodological issues in trial design and treatment delivery are now being addressed. In addition, recent experimental evidence is beginning to suggest an effect of cannabinoids on more fundamental processes important in MS, with evidence of anti-inflammation, encouragement of remyelination and neuroprotection. Trials are currently under way to test whether cannabinoids may have a longer term role in reducing disability and progression in MS, in addition to symptom amelioration, where indications are being established.


Multiple Sclerosis Multiple Sclerosis Patient Tolterodine Visual Analogue Score Tizanidine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No funding has been provided to prepare this review. There has been no involvement of any funding organisation or sponsor in any of the following: collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. Prof. J.P. Zajicek has previously received consultancy fees from IKF and Bayer-Schering. Dr V. Apostu has no conflicts of interest to declare. No other persons have made any substantial contributions to the work.


  1. 1.
    Mahlberg PG, Kim ES. Secretory vesicle formation in glandular trichomes of Cannabis sativa L. (Cannabaceae). Am J Bot 1992; 79: 166–73CrossRefGoogle Scholar
  2. 2.
    Work TS, Bergel F, Todd AR. The active principles of Cannabis indica resin: I. Biochem J 1939 Jan; 33(1): 123–7PubMedGoogle Scholar
  3. 3.
    Adams R, Pease DC, Cain CK, et al. Conversion of cannabi-diol to a product with marihuana activity: a type reaction for synthesis of analogous substances: conversion of cannabidiol to cannabinol. J Am Chem Soc 1940; 62(8): 2245–6CrossRefGoogle Scholar
  4. 4.
    Ghosh R, Todd AR, Wilkinson S. Cannabis indica, part IV: the synthesis of some tetrahydrodibenzopyran derivatives. J Chem Soc 1940; 1121-5Google Scholar
  5. 5.
    Adams R, Baker BR. Structure of cannabinol, V: a second method of synthesis of cannabinol. J Am Chem Soc 1940; 62(9): 2401CrossRefGoogle Scholar
  6. 6.
    Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646–7CrossRefGoogle Scholar
  7. 7.
    Mechoulam R, Shvo Y. The structure of cannabidiol. Tetrahedron 1963; 19: 2073–8CrossRefGoogle Scholar
  8. 8.
    Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561–4PubMedCrossRefGoogle Scholar
  9. 9.
    Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61–5PubMedCrossRefGoogle Scholar
  10. 10.
    Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 984–6Google Scholar
  11. 11.
    Pertwee R. Cannabinoid receptors and pain. Prog Neurobiol 2001;63: 569–611PubMedCrossRefGoogle Scholar
  12. 12.
    Begg M, Dale N, Llaudet E, et al. Modulation of the release of endogenous adenosine by cannabinoids in the myenteric plexus-longitudinal muscle preparation of the guineapig ileum. Br J Pharmacol 2002 Dec; 137(8): 1298–304PubMedCrossRefGoogle Scholar
  13. 13.
    Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology, XXVII: classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161–202PubMedCrossRefGoogle Scholar
  14. 14.
    Glass M, Faull RL, Dragunow M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77(2): 299–318PubMedCrossRefGoogle Scholar
  15. 15.
    Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995 Aug 15; 232(1): 54–61PubMedCrossRefGoogle Scholar
  16. 16.
    Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992 Dec 18; 258(5090): 1946–9PubMedCrossRefGoogle Scholar
  17. 17.
    Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83–90PubMedCrossRefGoogle Scholar
  18. 18.
    Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachido-noylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89–97PubMedCrossRefGoogle Scholar
  19. 19.
    Jhaveri MD, Richardson D, Chapman V. Endocanna-binoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007; 152: 624–32PubMedCrossRefGoogle Scholar
  20. 20.
    Bohme GA, Laville M, Ledent C, et al. Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience 2000; 95: 5–7PubMedCrossRefGoogle Scholar
  21. 21.
    Reibaud M, Obinu MC, Ledent C, et al. Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol 1999; 379: R1–2PubMedCrossRefGoogle Scholar
  22. 22.
    Zimmer A, Zimmer AM, Hohmann AG, et al. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 1999 May 11; 96(10): 5780–5PubMedCrossRefGoogle Scholar
  23. 23.
    Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401–4PubMedCrossRefGoogle Scholar
  24. 24.
    Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food in take. Nature (London) 2001 Apr 12; 410: 822–5CrossRefGoogle Scholar
  25. 25.
    Louw DF, Yang FW, Sutherland GR. The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res 2000 Feb 28; 857(1–2): 183–7PubMedCrossRefGoogle Scholar
  26. 26.
    Zhang M, Martin RB, Adler WM, et al. Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimm Pharmacol 2009 Jun; 4(2): 249–59CrossRefGoogle Scholar
  27. 27.
    Maresz K, Pryce G, Ponomarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007 Apr; 13(4): 492–7PubMedCrossRefGoogle Scholar
  28. 28.
    Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003 Oct; 126 (Pt 10): 2191–202PubMedCrossRefGoogle Scholar
  29. 29.
    Palazuelos J, Aguado T, Pazos MR, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain 2009 Nov; 132 (Pt 11): 3152–64PubMedCrossRefGoogle Scholar
  30. 30.
    Hampson AJ, Grimaldi M, Axelrod J, et al. Cannabidiol and (−)delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998; 95: 8268–73PubMedCrossRefGoogle Scholar
  31. 31.
    Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses on to Purkinje cells. Neuron 2001; 29: 717–27PubMedCrossRefGoogle Scholar
  32. 32.
    Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N-and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997; 78: 43–50PubMedGoogle Scholar
  33. 33.
    Molina-Holgado E, Vela JM, Arévalo-Martín A, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002 Nov 15; 22(22): 9742–53PubMedGoogle Scholar
  34. 34.
    Aréevalo-Martén A, Vela JM, Molina-Holgado E, et al. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003 Apr 1; 23(7): 2511–6Google Scholar
  35. 35.
    van Oosten BW, Killestein J, Mathus-Vliegen EM, et al. Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. Mult Scler 2004 Jun; 10(3): 330–1PubMedCrossRefGoogle Scholar
  36. 36.
    UNODC (United Nations Office on Drugs and Crime). Why should we care about cannabis? [online]. Available from URL: [Accessed 2010 Oct 10]
  37. 37.
    Zajicek J, Freeman, Porter B. Multiple sclerosis care: a practical manual. Oxford: Oxford University Press, 2007: 164Google Scholar
  38. 38.
    Clark AJ, Ware MA, Yazer E, et al. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004 Jun 8; 62(11): 2098–100PubMedCrossRefGoogle Scholar
  39. 39.
    Page SA, Verhoef MJ, Stebbins RA, et al. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 2003 Aug; 30(3): 201–5PubMedGoogle Scholar
  40. 40.
    Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des 2008; 14(23): 2326–36PubMedCrossRefGoogle Scholar
  41. 41.
    Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth 2008 Jul; 101(1): 59–68PubMedCrossRefGoogle Scholar
  42. 42.
    Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009 Feb; 156(3): 397–411PubMedCrossRefGoogle Scholar
  43. 43.
    Medicines and Healthcare products Regulatory Agency. Public assessment report [online]. Available from URL: [Accessed 2011 Jan 4]
  44. 44.
    McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manage 2005; 10 Suppl. A: 15A–22AGoogle Scholar
  45. 45.
    Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005; (168): 657-90Google Scholar
  46. 46.
    McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 Jul; 50(1): 121–7PubMedCrossRefGoogle Scholar
  47. 47.
    Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38(1): 44–8PubMedCrossRefGoogle Scholar
  48. 48.
    Heltberg A. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975; 51: 158–66PubMedGoogle Scholar
  49. 49.
    Cartlidge NE, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974; 23: 17–24PubMedCrossRefGoogle Scholar
  50. 50.
    A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis: United Kingdom Tizanidine Trial Group. Neurology 1994; 44 (11 Suppl. 9): S70-8Google Scholar
  51. 51.
    Smith C, Birnbaum G, Carter JL, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a doubleblind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994; 44(11 Suppl. 9): S34–42PubMedGoogle Scholar
  52. 52.
    Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000 Feb; 81(2): 164–9PubMedGoogle Scholar
  53. 53.
    Petro DJ, Ellenberger Jr C. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 1981 Aug-Sep; 21(8-9 Suppl. ): 413S–6SPubMedGoogle Scholar
  54. 54.
    Ungerleider JT, Andyrsiak T, Fairbanks L, et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7(1): 39–50PubMedCrossRefGoogle Scholar
  55. 55.
    Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurology 2002 May 14; 58(9): 1404–7PubMedCrossRefGoogle Scholar
  56. 56.
    Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003 Nov 8; 362(9395): 1517–26PubMedCrossRefGoogle Scholar
  57. 57.
    Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in Multiple Sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005 Dec; 76(12): 1664–9PubMedCrossRefGoogle Scholar
  58. 58.
    Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004 Aug; 10(4): 417–24PubMedCrossRefGoogle Scholar
  59. 59.
    Zajicek J, Reif M, Schnelle M. Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis: results of the MUSEC study [abstract no. P881]. Mult Scler 2009; 15: S274Google Scholar
  60. 60.
    Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004 Aug; 10(4): 434–41PubMedCrossRefGoogle Scholar
  61. 61.
    Collin C, Davies P, Mutiboko IK, et al., Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007 Mar; 14(3): 290–6PubMedCrossRefGoogle Scholar
  62. 62.
    Ambler Z, Davies P, Gasperini C, et al. A two-phase study of Sativex in the relief of spasticity due to multiple sclerosis: phase A single-blind response assessment followed by phase B double-blind, randomised, placebo-controlled, parallel-group study [abstract no. P844]. Mult Scler Sep 2009; 15: S258Google Scholar
  63. 63.
    Wissel J, Haydn T, Müller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006 Oct; 253(10): 1337–41PubMedCrossRefGoogle Scholar
  64. 64.
    Freeman RM, Adekanmi O, Waterfield MR, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006 Nov; 17(6): 636–41PubMedCrossRefGoogle Scholar
  65. 65.
    Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004 Apr 13; 62(7): 1105–9PubMedCrossRefGoogle Scholar
  66. 66.
    Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? A randomised double blind placebo controlled crossover trial. BMJ 2004 Jul 31; 329(7460): 253PubMedCrossRefGoogle Scholar
  67. 67.
    Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia 2004 May; 59(5): 440–52PubMedCrossRefGoogle Scholar
  68. 68.
    Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005 Sep 27; 65(6): 812–9PubMedCrossRefGoogle Scholar
  69. 69.
    Gross RA, Johnston KC. Levels of evidence: taking neurology to the next level. Neurology 2009; 72: 8–10PubMedCrossRefGoogle Scholar
  70. 70.
    Wilner AN. Lost in a jungle of evidence: we need a compass. Practice parameters and technology assessments —what they are, what they are not, and why you should care [letter]. Neurology 2009 Oct 20; 73(16): 1337; author reply 1337-8PubMedGoogle Scholar
  71. 71.
    Pincus MM. Lost in a jungle of evidence: we need a compass [letter]. Neurology 2009 Oct 20; 73(16): 1338; author reply 1338-9PubMedCrossRefGoogle Scholar
  72. 72.
    French J, Gronseth G. Lost in a jungle of evidence: we need a compass. Neurology 2008 Nov 11; 71(20): 1634–8PubMedCrossRefGoogle Scholar
  73. 73.
    Fowler CJ, Panicker JN, Drake M et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J 2009; 85: 552–9PubMedCrossRefGoogle Scholar
  74. 74.
    Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986 May; 135(5): 966–8PubMedGoogle Scholar
  75. 75.
    Ethans KD, Nance PW, Bard RJ, et al. Efficacy and safety of tolterodine in people with neurogenic detrusor over-activity. J Spinal Cord Med 2004; 27(3): 214–8PubMedGoogle Scholar
  76. 76.
    Brady CM, DasGupta R, Dalton C, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004 Aug; 10(4): 425–33PubMedCrossRefGoogle Scholar
  77. 77.
    Koller WC. Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol 1984 Mar; 41(3): 280–1PubMedCrossRefGoogle Scholar
  78. 78.
    Koch M, Mostert J, Heersema D, et al. Tremor in multiple sclerosis. J Neurol 2007 Feb; 254(2): 133–45PubMedCrossRefGoogle Scholar
  79. 79.
    Charles PD, Esper GJ, Davis TL, et al. Classification of tremor and update on treatment. Am Fam Physician 1999 Mar 15; 59(6): 1565–72PubMedGoogle Scholar
  80. 80.
    Striano P, Coppola A, Vacca G, et al. Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study. J Neurol 2006 Jun; 253(6): 762–6PubMedCrossRefGoogle Scholar
  81. 81.
    Feys P, D’hooghe M, Nagels G, et al. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. Mult Scler 2009 Mar; 15(3): 371–8PubMedCrossRefGoogle Scholar
  82. 82.
    Meinck HM, Schönle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989 Feb; 236(2): 120–2PubMedCrossRefGoogle Scholar
  83. 83.
    Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983 Jun; 13(6): 669–71PubMedCrossRefGoogle Scholar
  84. 84.
    Stahl JS, Rottach KG, Averbuch-Heller L, et al. A pilot study of gabapentin as treatment for acquired nystagmus. Neuroophthalmology 1996 Apr; 16(2): 107–13PubMedCrossRefGoogle Scholar
  85. 85.
    Thurtell MJ, Joshi AC, Leone AC, et al. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol 2010 May; 67(5): 676–80PubMedGoogle Scholar
  86. 86.
    Bandini F, Castello E, Mazzella L, et al. Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: how valid is the GABA-ergic hypothesis? J Neurol Neurosurg Psychiatry 2001 Jul; 71(1): 107–10PubMedCrossRefGoogle Scholar
  87. 87.
    Schon F, Hart PE, Hodgson TL, et al. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 1999; 53: 2209–10PubMedCrossRefGoogle Scholar
  88. 88.
    Zajicek JP, Ingram WM, Vickery J, et al. Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort. BMC Neurol 2010 Oct 7; 10: 88PubMedCrossRefGoogle Scholar
  89. 89.
    Pöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008; 22(4): 291–324PubMedCrossRefGoogle Scholar
  90. 90.
    Brichetto G, Messmer Uccelli M, Mancardi GL, et al. Symptomatic medication use in multiple sclerosis. Mult Scler 2003 Oct; 9(5): 458–60PubMedCrossRefGoogle Scholar
  91. 91.
    Solaro C. Epidemiology and treatment of pain in multiple sclerosis subjects. Neurol Sci 2006 Sep; 27 Suppl. 4: s291–3CrossRefGoogle Scholar
  92. 92.
    Breuer B, Pappagallo M, Knotkova H, et al. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther 2007 Sep; 29(9): 2022–30PubMedCrossRefGoogle Scholar
  93. 93.
    Silver M, Blum D, Grainger J, et al. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage 2007 Oct; 34(4): 446–54PubMedCrossRefGoogle Scholar
  94. 94.
    Solaro C, Brichetto G, Battaglia MA, et al. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurol Sci 2005 Feb; 25(6): 307–10PubMedCrossRefGoogle Scholar
  95. 95.
    Solaro C, Uccelli MM, Guglieri P, et al. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler 2000 Jun; 6(3): 192–3PubMedGoogle Scholar
  96. 96.
    Solaro C, Boehmker M, Tanganelli P. Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. J Neurol 2009 Oct; 256(10): 1773–4PubMedCrossRefGoogle Scholar
  97. 97.
    Rossi S, Mataluni G, Codecà C, et al. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol 2009 Mar; 16(3): 360–6PubMedCrossRefGoogle Scholar
  98. 98.
    DMKG Study Group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol 2003 May; 250(5): 542–5CrossRefGoogle Scholar
  99. 99.
    Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007 Sep; 29(9): 2068–79PubMedCrossRefGoogle Scholar
  100. 100.
    Iskedjian M, Bereza B, Gordon A, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007 Jan; 23(1): 17–24PubMedCrossRefGoogle Scholar
  101. 101.
    Greenberg HS, Werness SA, Pugh JE, et al. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994 Mar; 55(3): 324–8PubMedCrossRefGoogle Scholar
  102. 102.
    Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006 Oct; 12(5): 639–45PubMedCrossRefGoogle Scholar
  103. 103.
    Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008; 178(13): 1669–78PubMedCrossRefGoogle Scholar
  104. 104.
    Papathanasopoulos P, Messinis L, Lyros E, et al. Multiple sclerosis, cannabinoids, and cognition. J Neuropsychiatr Clin Neurosci 2008 Dec; 20(1): 36–51CrossRefGoogle Scholar
  105. 105.
    Langdon DW, Thompson AJ, Johnson KP, et al. The psychological effects of cannabis in MS: impact on cognition, pain, mood and fatigue [abstract]. Mult Scler ECTRIMS 2003; 9: S27Google Scholar
  106. 106.
    Kurzthaler I, Bodner T, Kemmler G, et al. The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol 2005; 20: 291–3PubMedCrossRefGoogle Scholar
  107. 107.
    Hobart JC, Riazi A, Thompson AJ, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 2006 Jan; 129 (Pt 1): 224–34PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Clinical Neurology Research GroupPeninsula College of Medicine and Dentistry, Peninsula Medical SchoolPlymouthUK
  2. 2.Clinical Neurology Research GroupPeninsula Medical SchoolPlymouthUK

Personalised recommendations